Mitochon Pharmaceuticals Mitochon Pharmaceuticals
  • Company
  • Science & Technology
  • Pipeline
  • News & Publications
  • Contact

Mitochon Pipeline

Compounds

MP101

Huntington’s Disease

Duchenne Muscular Dystrophy

Optic Neuritis

MP201

Multiple Sclerosis

Parkinson’s Disease

Pre-Clinical Efficacy

IND Enabling Activities

Phase I

Phase II

  • No Widgets

    "Secondary" needs some widgets.

  • Mitochon Pharmaceuticals Mitochon Pharmaceuticals
    • MP 201:
    • Multiple Sclerosis

    Multiple Sclerosis

    • No known etiology.
    • Autoimmune disorder of the CNS.
    • Antibodies attack the myelin sheaths surrounding and protecting the axons.
    • Intermitting episodes, called Relapsing Remitting, the body repairs itself to some degree.
    • Chronic attacks, called Progressive, is the most severe where axons/neurons die off.
    • Voluntary movement is disrupted and involuntary control of bladder and bowels.

    OUR DATA SHOWS:
    MP101 and MP201 significantly improve Clinical Scores (block paralysis) in the gold standard EAE model.
    MP101 and MP201 prevents demyelination and destruction of the axon in the autoimmune independent cuprizone model.
    MP101 and MP201 have a striking effect in preserving body movement and behavior compared to placebo (video).

    MP101 and MP201 attenuates Multiple Sclerosis using the EAE Model.

    *P values by Ordinal Regression
    MP101 5mpk = 0.0192
    MP201 80mpk = 0.00014

    MP101 and MP201 Protect of Axons in Cuprizone Model.

    MP101 and MP201 has a striking effect protecting against both demyelination and axonal loss in the autoimmune independent cuprizone model compared to placebo.

    Mitochon Pharmaceuticals, Inc.
    970 Cross Lane
    Blue Bell, PA 19422
    © 2021 Mitochon Pharmaceuticals, All Rights Reserved
    Website designed and managed by WP Cinch
    PageLines